Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORWARD trial of fibrinogenase after successful mechanical thrombectomy for acute ischemic stroke
ChiCTR2500102258Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Apr 2025
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of batroxobin in ischemic stroke (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Functional independence rate at 90 days after randomization and Symptomatic intracranial hemorrhage within 48 hours after randomization. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
batroxobin
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2500102258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102258.